Evidence map›Paper›PMID 30414104›Full record

ArticleMolecular biology reports2019

Inherent anti-HIV activity of biocompatible anionic citrate-PEG-citrate dendrimer.

Mohammad Reza Kandi, Javad Mohammadnejad, Mehdi Shafiee Ardestani, Rezvan Zabihollahi, Sepehr Soleymani, Mohammad Reza Aghasadeghi, Kazem Baesi

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Development ofJournal of cancer research and clinical oncology · 2023
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Mohammad Reza KandiDepartment of Life Science Engineering, Faculty of New Science and Technology, University of Tehran, Tehran, Iran.
Javad MohammadnejadDepartment of Life Science Engineering, Faculty of New Science and Technology, University of Tehran, Tehran, Iran.
Mehdi Shafiee ArdestaniDepartment of Radiopharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Rezvan ZabihollahiHepatitis and AIDS Department, Pasteur Institute of Iran, P. O. Box 14115-331, Tehran, Iran.
Sepehr SoleymaniHepatitis and AIDS Department, Pasteur Institute of Iran, P. O. Box 14115-331, Tehran, Iran.
Mohammad Reza AghasadeghiHepatitis and AIDS Department, Pasteur Institute of Iran, P. O. Box 14115-331, Tehran, Iran.
Kazem BaesiHepatitis and AIDS Department, Pasteur Institute of Iran, P. O. Box 14115-331, Tehran, Iran. kbaesi@gmail.com.ORCID http://orcid.org/0000-0001-5483-0008
Pasteur Institute of Iran · IRUniversity of Tehran · IRTehran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of new combinations to empower better protection against HIV infection is particularly important. Anionic polymers can block HIV infection. In the current study, first generation (G1) and second generation (G2) novel water-soluble anionic citrate-PEG-citrate dendrimers were synthesized and characterized with Fourier-transform infrared spectroscopy (FTIR), nuclear magnetic resonance spectroscopy (NMR), and dynamic light scattering (DLS) methods. After the biocompatibility of the G2 dendrimer was determined, its antiviral activity was evaluated. This function may contribute to the peripheral groups of this dendrimer (carboxylate group). In order to measure the inhibitory effect of G2 on HIV infection, both pre-treatment (treated with G2 dendrimer before HIV infection) and co-treatment (simultaneously treated with G2 dendrimer and HIV infection) were used in vitro. The results showed the good synthesis of the G2 dendrimer, and the dendrimer showed antiviral properties (ICC50:0.4 mM) and low toxicity (CC50:0.6 mM) at high concentrations. A strong inhibitory effect was found when the co-treatment approach was used. This study achieved promising results which encourage the use of G2 dendrimers as anti-HIV agents.

Indexed as

Anti-HIV AgentsCitratesCitric AcidDendrimersHIV-1HIV InfectionsHumansPolyelectrolytesPolyethylene GlycolsPolymersAnti-HIV AgentsCitratesCitric AcidDendrimersPolyelectrolytesPolyethylene GlycolsPolymersBiocompatibleDendrimerHIV inhibitionPolyanionic polymer

Identifiers

PMID30414104
OpenAlexW2900081915

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.